MAR-QUETIAPINE TABLET (IMMEDIATE RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
16-11-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
QUETIAPINE (QUETIAPINE FUMARATE)
Inapatikana kutoka:
MARCAN PHARMACEUTICALS INC
ATC kanuni:
N05AH04
INN (Jina la Kimataifa):
QUETIAPINE
Kipimo:
100MG
Dawa fomu:
TABLET (IMMEDIATE RELEASE)
Tungo:
QUETIAPINE (QUETIAPINE FUMARATE) 100MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100/500
Dawa ya aina:
Prescription
Eneo la matibabu:
ATYPICAL ANTIPSYCHOTICS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0131858002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2013-01-16
Tabia za bidhaa
Page1 of58
PRODUCT MONOGRAPH
INCLUDING PATIENTMEDICATIONINFORMATION
Pr
MAR-QUETIAPINE
QuetiapineTablets
Immediate-ReleaseTablets,25, 100, 200 and300mg (asquetiapinefumarate),
OralUse
USP
AntipsychoticAgent
MarcanPharmaceuticals Inc.
2GurdwaraRoad,Suite#112
Ottawa,Ontario
K2E1A2 Canada
Date of InitialAuthorization:
JAN 16,2013
Date ofRevision:
NOV16,2022
SubmissionControl No.: 269102
Page2 of58
RECENT MAJORLABELCHANGES
7 WARNINGS ANDPRECAUTIONS- Musculoskeletal- Rhabdomyolysis
11/2022
7 WARNINGS ANDPRECAUTIONS – Psychiatric
11/2022
7 WARNINGS ANDPRECAUTIONS - Skin
11/2022
TABLE OF CONTENTS
Sectionsorsubsectionsthatare notapplicableat the time of authorization
are notlisted
1.
INDICATIONS
......................................................................................................................4
1.1
Pediatrics...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2.
CONTRAINDICATIONS
.......................................................................................................4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
......................................................... 5
4.
DOSAGE AND ADMINISTRATION
.....................................................................................5
4.1
Dosing
Considerations...................................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..........................................................5
4.4
Administration........................................................................................................
7
4.5
Missed
Dose...................................................................................................................
7
5.
OVERDOSAGE
........................................................................................................................
7
6.
DOSA
Soma hati kamili
